Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma

Study:

Phase II to Treat Multiple Myeloma Patients With Cytoxan and Vincristine After Cycling Myeloma Cells With rHuGM-CSF

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. GM-CSF may make cancer cells more sensitive to the effects of chemotherapy. Combining more than one drug with GM-CSF may kill more tumor cells.

Purpose:

Phase II trial to study the effectiveness of combination chemotherapy, consisting of cyclophosphamide plus vincristine, following GM-CSF in treating patients with multiple myeloma that has not responded to previous treatment.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Multiple Myeloma and Plasma Cell Neoplasm Biological: sargramostim
Drug: cyclophosphamide
Drug: prednisone
Drug: vincristine sulfate
Phase 2

Verified by The Cleveland Clinic March, 2001

Sponsored by: The Cleveland Clinic
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00003490

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

Mohamad A. Hussein, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site